Sialix Changes Name to Siamab Therapeutics

Sialix, Inc., a biotechnology company developing cancer immunotherapies, today announced that the company has changed its name to Siamab Therapeutics. In addition, the company announced that it has received an additional $2 million in funding as part of its Series B, bringing the total raised to $6 million.

For more: Sialix Changes Name to Siamab Therapeutics